Bonnet Crystel, Kaltimbacher Valérie, Ellouze Sami, Augustin Sébastien, Bénit Paule, Forster Valérie, Rustin Pierre, Sahel José-Alain, Corral-Debrinski Marisol
Laboratoire de Physiopathologie Cellulaire et Moléculaire de la Rétine, INSERM U592, Université Pierre et Marie Curie (UPMC-Paris6), Hôpital St. Antoine-Bât. Kourilsky, 184 rue du Faubourg Saint-Antoine, 75571 Paris Cedex 12, France.
Rejuvenation Res. 2007 Jun;10(2):127-44. doi: 10.1089/rej.2006.0526.
The possibility of synthesizing mitochondrial DNA (mtDNA)-coded proteins in the cytosolic compartment, called allotopic expression, provides an attractive option for genetic treatment of human diseases caused by mutations of the corresponding genes. However, it is now appreciated that the high hydrophobicity of proteins encoded by the mitochondrial genome represents a strong limitation on their mitochondrial import when translated in the cytosol. Recently, we optimized the allotopic expression of a recoded ATP6 gene in human cells, by forcing its mRNA to localize to the mitochondrial surface. In this study, we show that this approach leads to a long-lasting and complete rescue of mitochondrial dysfunction of fibroblasts harboring the neurogenic muscle weakness, ataxia and retinitis Pigmentosa T8993G ATP6 mutation or the Leber hereditary optic neuropathy G11778A ND4 mutation. The recoded ATP6 gene was associated with the cis-acting elements of SOD2, while the ND4 gene was associated with the cis-acting elements of COX10. Both ATP6 and ND4 gene products were efficiently translocated into the mitochondria and functional within their respective respiratory chain complexes. Indeed, the abilities to grow in galactose and to produce adenosine triphosphate (ATP) in vitro were both completely restored in fibroblasts allotopically expressing either ATP6 or ND4. Notably, in fibroblasts harboring the ATP6 mutation, allotopic expression of ATP6 led to the recovery of complex V enzymatic activity. Therefore, mRNA sorting to the mitochondrial surface represents a powerful strategy that could ultimately be applied in human therapy and become available for an array of devastating disorders caused by mtDNA mutations.
在胞质区室中合成线粒体DNA(mtDNA)编码蛋白的可能性,即所谓的异位表达,为因相应基因突变导致的人类疾病的基因治疗提供了一个有吸引力的选择。然而,现在人们认识到,线粒体基因组编码的蛋白具有高度疏水性,这对其在胞质中翻译后的线粒体导入构成了严重限制。最近,我们通过迫使重新编码的ATP6基因的mRNA定位于线粒体表面,优化了其在人类细胞中的异位表达。在这项研究中,我们表明,这种方法能够持久且完全地挽救携带神经源性肌无力、共济失调和色素性视网膜炎T8993G ATP6突变或Leber遗传性视神经病变G11778A ND4突变的成纤维细胞的线粒体功能障碍。重新编码的ATP6基因与SOD2的顺式作用元件相关联,而ND4基因与COX10的顺式作用元件相关联。ATP6和ND4基因产物均能有效地转运到线粒体中,并在各自的呼吸链复合物中发挥功能。事实上,在异位表达ATP6或ND4的成纤维细胞中,在半乳糖中生长的能力和体外产生三磷酸腺苷(ATP)的能力均完全恢复。值得注意的是,在携带ATP6突变的成纤维细胞中,ATP6的异位表达导致了复合物V酶活性的恢复。因此,mRNA分选至线粒体表面是一种强大的策略,最终可能应用于人类治疗,并可用于治疗一系列由mtDNA突变引起的毁灭性疾病。